Page 45 - Read Online

Olivera et al. Cancer Drug Resist 2019;2:53-68 I http://dx.doi.org/10.20517/cdr.2018.25 Page 67

vomiting. Drugs 2016;76:1719-35.
36. Sanwald P, David M, Dow J. Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of dolasetron.
Comparison with other indole-containing 5-HT3 antagonists. Drug Metab Dispos 1996;24:602-9.
37. Bloomer JC, Baldwin SJ, Smith GJ, Ayrton AD, Clarke SE, et al. Characterisation of the cytochrome P450 enzymes involved in the in
vitro metabolism of granisetron. Br J Clin Pharmacol 1994;38:557-66.
38. Gaedigk A, Simon S, Pearce R, Bradford LD, Kennedy MJ, et al. The CYP2D6 activity score: translating genotype information into a
qualitative measure of phenotype. Clin Pharmacol Ther 2008;83:234-42.
39. Sanchez Spitman AB, Moes DJAR, Gelderblom H, Dezentje VO, Swen JJ, et al. Effect of CYP3A4*22, CYP3A5*3, and CYP3A
combined genotypes on tamoxifen metabolism. Eur J Clin Pharmacol 2017;73:1589-98.
40. Desta Z, Ward BA, Soukhova NV, Flockhart DA. Comprehensive evaluation of tamoxifen sequential biotransformation by the human
cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther 2004;310:1062-75.
41. Thota K, Prasad K, Basaveswara RMV. Detection of cytochrome P450 polymorphisms in breastcancer patients may impact on
tamoxifen therapy. Asian Pac J Cancer Prev 2018;19:343-50.
42. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in early breast cancer: patient-
level meta-analysis of the randomised trials. Lancet 2015;386:1341-52.
43. Maor R, Sara JDS, Wanous AA, Maor E, Pruthi S, et al. Attenuated peripheral endothelial function among women treated with
aromatase inhibitors for breast cancer. Coron Artery Dis 2018;29:687-93.
44. Hertz DL, Deal A, Ibrahim JG, Walko CM, Weck KE, et al. Tamoxifen dose escalation in patients with diminished CYP2D6 activity
normalizes endoxifen concentrations without increasing toxicity. Oncologist 2016;21:795-803.
45. Ho GY, Woodward N, Coward JIG. Cisplatin versus carboplatin: comparative review of therapeutic management in solid malignancies.
Crit Rev Oncol Hematol 2016;102:37-46.
46. Lui G, Bouazza N, Denoyelle F, Moine M, Brugières L, et al. Association between genetic polymorphisms and platinum-induced
ototoxicity in children. Oncotarget 2018;9:30883-93.
47. Langer T, am Zehnhoff-Dinnesen A, Radtke S, Meitert J, Zolk O. Understanding platinum-induced ototoxicity. Trends Pharmacol Sci
2013;34:458-69.
48. Liberman PHP, Goffi-Gomez MVS, Schultz C, Jacob PL, de Paula CAA, et al. Contribution of the GSTP1 c.313A>G variant to hearing
loss risk in patients exposed to platin chemotherapy during childhood. Clin Transl Oncol 2018; doi: 10.1007/s12094-018-1964-7.
49. Brown AL, Lupo PJ, Okcu MF, Lau CC, Rednam S, et al. SOD2 genetic variant associated with treatment-related ototoxicity in
cisplatin-treated pediatric medulloblastoma. Cancer Med 2015;4:1679-86.
50. Lopes-Aguiar L, Costa EFD, Nogueira GAS, Lima TRP, Visacri MB, et al. XPD c.934G>A polymorphism of nucleotide excision
repair pathway in outcome of head and neck squamous cell carcinoma patients treated with cisplatin chemoradiation. Oncotarget
2017;8:16190-201.
51. Drögemöller BI, Monzon JG, Bhavsar AP, Borrie AE, Brooks B, et al. Association between SLC16A5 genetic variation and cisplatin-
induced ototoxic effects in adult patients with testicular cancer. JAMA Oncol 2017;3:1558-62.
52. Lanvers-Kaminsky C, Sprowl JA, Malath I, Deuster D, Eveslage M, et al. Human OCT2 variant c.808G>T confers protection effect
against cisplatin-induced ototoxicity. Pharmacogenomics 2015;16:323-32.
53. Ross CJD, Katzov-Eckert H, Dubé MP, Brooks B, Rassekh SR, et al. Genetic variants in TPMT and COMT are associated with hearing
loss in children receiving cisplatin chemotherapy. Nat Genet 2009;41:1345-9.
54. Pussegoda K, Ross CJ, Visscher H, Yazdanpanah M, Brooks B, et al. Replication of TPMT and ABCC3 genetic variants highly
associated with cisplatin-induced hearing loss in children. Clin Pharmacol Ther 2013;94:243-51.
55. Yang JJ, Lim JYS, Huang J, Bass J, Wu J, et al. The role of inherited TPMT and COMT genetic variation in cisplatin-induced
ototoxicity in children with cancer. Clin Pharmacol Ther 2013;94:252-9.
56. Thiesen S, Yin P, Jorgensen AL, Zhang JE, Manzo V, et al. TPMT, COMT and ACYP2 genetic variants in paediatric cancer patients
with cisplatin-induced ototoxicity. Pharmacogenet Genomics 2017;27:213-22.
57. Oliveira E, Quental S, Alves S, Amorim A, Prata MJ. Do the distribution patterns of polymorphisms at the thiopurine S-methyltransferase
locus in sub-Saharan populations need revision? Hints from Cabinda and Mozambique. Eur J Clin Pharmacol 2007;63:703-6.
58. Hagleitner MM, Coenen MJH, Patino-Garcia A, De Bont ESJM, Gonzalez-Neira A, et al. Influence of genetic variants in TPMT and
COMT associated with cisplatin induced hearing loss in patients with cancer: two new cohorts and a meta-analysis reveal significant
heterogeneity between cohorts. PLoS One 2014;9:e115869.
59. Krynetski E, Evans WE. Drug methylation in cancer therapy: lessons from the TPMT polymorphism. Oncogene 2003;22:7403-13.
60. Stern JW, Bunin N. Prospective study of carboplatin-based chemotherapy for pediatric germ cell tumors. Med Pediatr Oncol
2002;39:163-7.
61. Shaikh F, Nathan PC, Hale J, Uleryk E, Frazier L. Is there a role for carboplatin in the treatment of malignant germ cell tumors? A
systematic review of adult and pediatric trials. Pediatr Blood Cancer 2013;60:587-92.
62. Kolinsky DC, Hayashi SS, Karzon R, Mao J, Hayashi RJ. Late onset hearing loss: a significant complication of cancer survivors treated
with cisplatin containing chemotherapy regimens. J Pediatr Hematol Oncol 2010;32:119-23.
63. Grewal S, Merchant T, Reymond R, McInerney M, Hodge C, et al. Auditory late effects of childhood cancer therapy: a report from the
Children’s Oncology Group. Pediatrics 2010;125:e938-50.
64. Ellison LF, Pogany L, Mery LS. Childhood and adolescent cancer survival: a period analysis of data from the Canadian Cancer Registry.
Eur J Cancer 2007;43:1967-75.